Ligustrazine activate the PPAR-γ pathway and play a protective role in vascular calcification

Li, Hui; Yang, Min

doi:10.1177/17085381211051477

Cited by 3 publications

(4 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Otherwise, vessel inflammation caused by the chemokine signaling pathway and focal adhesion is one major contributor to VC formation 1–3,33 . On the other hand, activating the PPAR signaling pathway can shield VSMCs from the osteogenic differentiation potential during the VC process 34 . It has also been proven that Apelin can reduce VC in VMSC that comes from CKD 35 .…”

Section: Discussionmentioning

confidence: 99%

“…[1][2][3]33 On the other hand, activating the PPAR signaling pathway can shield VSMCs from the osteogenic differentiation potential during the VC process. 34 It has also been proven that Apelin can reduce VC in VMSC that comes from CKD. 35 In the same way, the use of metformin or other AMPK activators can improve the condition of calcification deposits in blood vessels.…”

Section: Degs and Kegg Pathways In Both As And Ckdmentioning

confidence: 99%

See 1 more Smart Citation

In silico analysis and verification of critical genes related to vascular calcification in multiple diseases

Li,

Ruan,

Yang

et al. 2023

Cell Biochemistry & Function

View full text Add to dashboard Cite

Identifying a functional molecular therapeutic target of vascular calcification (VC) that will not affect normal osteogenic differentiation is a challenge. To address this aim, we screened the differentially expressed genes (DEGs) in different VC conditions, including endothelial‐osteogenic transition (EOT) (GSE167962), chronic kidney disease (CKD), and atherosclerosis (AS) (GSE159832). KEGG pathways, protein–protein interactions, and hub genes were also analyzed. The intersecting DEGs among the EOT, CKD, and AS groups were verified by quantitative reverse transcription polymerase chain reaction and immunohistochemistry in a DOCA‐salt hypertension mouse model. The phosphoinositide 3‐kinase–protein kinase B signaling pathway, ECM‐receptor interaction, chemokine signaling pathway, and focal adhesion were enriched in EOT and AS‐induced VC. ECM‐receptor interaction, PPAR signaling pathway, apelin signaling pathway, AMPK signaling pathway, adipocytokine signaling pathway, and cholesterol metabolism were enriched in CKD and AS‐induced VC. C4b, Cebpa, Lyz2, and Spp1 were also upregulated in EOT, CKD, AS, and hypertension. This study identified promising molecular targets for VC therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Degs and Kegg Pathways In Both As And Ckdmentioning

confidence: 99%

In silico analysis and verification of critical genes related to vascular calcification in multiple diseases

Li,

Ruan,

Yang

et al. 2023

Cell Biochemistry & Function

View full text Add to dashboard Cite

show abstract

“…Ligustrazine is a bioactive alkaloid extracted from the traditional Chinese herbal medicine Ligusticum Chuanxiong Hort, which has long been used to treat neurovascular, cardiovascular, and liver diseases in China (10)(11)(12)(13). Ligustrazine is also an approved drug in China for rheumatoid arthritis, ranked first according to the synergistic score (14).…”

Section: Western Blottingmentioning

confidence: 99%

“…Ligustrazine has been widely used in the clinical treatment of neurovascular, cardiovascular, and liver diseases in China (20,21). In addition to the application of ligustrazine in the traditional field, some new pharmacological activities have been found, such as free radicals, improved microcirculation, and antitumor effects (10)(11)(12)(13)(14).…”

Section: Effect Of Ligustrazine On Proliferation Migration and Invasi...mentioning

confidence: 99%

Ligustrazine Inhibits the Migration and Invasion of Renal Cell Carcinoma

Zhang

Wang²,

Cao³

et al. 2023

jkcvhl

View full text Add to dashboard Cite

Ligustrazine is a Chinese herb (Chuanxiong) approved for use as a medical drug in China. Recent evidence suggests that ligustrazine has promising antitumor properties. Our preliminary results showed that ligustrazine could inhibit the growth of human renal cell carcinoma (RCC) cell lines. However, the complicated molecular mechanism has not been fully revealed. Therefore, the purpose of this study to investigate the mechanism of ligustrazine resistance in human RCC cells. Cell proliferation, migration, invasion, and colony-formation ability of RCC cells A498 were detected by MTT assay, clonal formation rates, and transwell chamber assay in vitro. The expression of epithelial–mesenchymal transition (EMT)–related proteins were analyzed using western blot test. The effect of ligustrazine on the growth of A498 cells in nude mice was investigated in vivo. Our results showed that ligustrazine could significantly inhibit the proliferation, migration, and invasion of A498 both in vivo and vitro. Western blot analysis showed that the expressions of EMT-related, N-cadherin, snail, and slug proteins were significantly decreased in A498 in the ligustrazine treatment group. This study indicated that ligustrazine could significantly inhibit the malignant biological behaviors of RCC cell lines, possibly by inhibiting the EMT process.

show abstract

Proanthocyanidin A2 attenuates the activation of hepatic stellate cells by activating the PPAR-γ signalling pathway

Xiao,

Li,

Wang

et al. 2023

Autoimmunity

View full text Add to dashboard Cite

Ligustrazine activate the PPAR-γ pathway and play a protective role in vascular calcification

Cited by 3 publications

References 34 publications

In silico analysis and verification of critical genes related to vascular calcification in multiple diseases

In silico analysis and verification of critical genes related to vascular calcification in multiple diseases

Ligustrazine Inhibits the Migration and Invasion of Renal Cell Carcinoma

Proanthocyanidin A2 attenuates the activation of hepatic stellate cells by activating the PPAR-γ signalling pathway

Contact Info

Product

Resources

About